SuperSonic Imagine said today said it won regulatory approval in Japan for its most recent Aixplorer ultrasound system, which includes new features that allow for the evaluation of liver disease, prostate cancer, obstetrics and musculoskeletal assessment.
A new line of ultrasound probes were included in the approval, as well as the company’s Anigo Planewave UltraSensitive microvascular visualization program.
The Angio P.L.U.S. system is designed to provide improved microvascular imaging through increased color sensitivity and spatial resolutions, as well as increases in the detail of real-time flow information available during ultrasound diagnostic exams, the company said.
“We are pleased to have received approval for the latest innovations on Aixplorer, our ultrasound system that has been widely adopted throughout Japan with the help of our partner Konica Minolta. Japan is the third largest ultrasound market in the world, therefore securing approval for these advanced technologies is critical milestone for our continued success,” chief innovation officer Jacques Souquet said in a press release.
In March, SuperSonic Imagine said it inked a U.S. distribution deal with Sandhill Scientific to distribute its Aixplorer ShearWave Elastography-equipped ultrasound system designed to assess liver disease, along with releasing its 2015 earnings.
Through the agreement, Sandhill will have rights to sell the Aixplorer ultrasound system to gastroenterologists and hepatologists from March 14, while SuperSonic Imagine will keep its direct sales force targeted on radiology, breast and other clinical segments, the company said.
The company also announced its 2015 earnings, seeing losses grow faster than revenue for the year compared to 2014. SuperSonic Imagine reported losses of $14 million (EU €12.7 million) on sales of $24 million (EU €21.7 million) for the year..
That amounts to a 14.9% growth in losses as sales grew only 0.6% compared with 2014.